ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma

NCT00420888 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

526

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: ABR-217620/naptumomab estafenatox
DRUG: IFN-alpha

Sponsor

Active Biotech AB